Business Context and Reporting Period
This Form 8-K filing by EyePoint Pharmaceuticals, Inc. (the "Company") reports on events occurring on July 31, 2018, with the report dated August 3, 2018. The filing primarily addresses the appointment of a new Chief Financial Officer and the associated compensatory arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation details:
- Annual Base Salary: $425,000
- Target Annual Bonus: 40% of base salary
- Stock Options: 385,000 shares at an exercise price of $2.22 per share
- Restricted Stock Units (RSUs): 225,000 performance-based units
Material Changes
The primary material change is the appointment of David Price as Chief Financial Officer, effective August 1, 2018. Mr. Price replaces the previous CFO (not named in this text) and brings over 25 years of experience in healthcare, investment banking, and accounting. The equity awards granted were made outside the Company's 2016 Long Term Equity Incentive Plan as an inducement material to his employment.
Outlook, Risks, and Unusual Items
Management Commentary: The Board appointed Mr. Price to leverage his extensive background, including prior CFO roles at Concordia International Corp., Bioventus LLC, EDGAR Online Inc., and Cornerstone Therapeutics, Inc.
Compensatory Arrangements and Risks:
- Termination Benefits: In the event of termination without "cause" or for "good cause," Mr. Price is entitled to 12 months of base salary (or 6 months if terminated within the first year), 100% of the target bonus (or 50% for a "One Year Termination"), and health premium reimbursements.
- Change of Control: Unvested options and restricted stock will immediately accelerate and vest in full upon a change of control, provided Mr. Price is employed on that date.
- Restrictions: Mr. Price is subject to non-compete, non-solicitation, and confidentiality agreements.
Investor Verification Checklist
- Verify the specific performance metrics for the 225,000 performance-based RSUs, which are to be determined within 30 days of the start date.
- Review the full text of the Employment Agreement (Exhibit 10.1) for detailed definitions of "cause," "good cause," and "change of control."
- Confirm the impact of the new CFO appointment on the Company's strategic financial planning and operational execution.
- Check subsequent filings for the vesting schedule confirmation of the 385,000 stock options.